Viracta Therapeutics, Inc. (VIRX)

Viracta Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	17.32	24.33	15.44	5.35	3.19
Research & Development	33.37	26.26	23.86	13.47	8.86
Operating Expenses	50.69	50.59	39.3	18.82	12.06
Operating Income	-50.69	-50.59	-39.3	-18.82	-12.06
Interest Expense	-3.7	-0.58	-0.49	-0.22	-1.66
Interest & Investment Income	3.35	1.17	0.04	0.05	0.06
Other Non Operating Income (Expenses)	-0.01	0.8	-0.29	-0.03	0.01
EBT Excluding Unusual Items	-51.06	-49.2	-40.04	-19.02	-13.64
Gain (Loss) on Sale of Assets	-	-	13.5	-	-
Other Unusual Items	-	-	0.26	-	0.08
Pretax Income	-51.06	-49.2	-114.76	-19.02	-13.56
Net Income	-51.06	-49.2	-114.76	-19.02	-13.56
Net Income to Common	-51.06	-49.2	-114.76	-19.02	-13.56
Shares Outstanding (Basic)	39	38	32	0	2
Shares Outstanding (Diluted)	39	38	32	0	2
Shares Change (YoY)	2.21%	18.58%	9714.39%	-86.22%	145.73%
EPS (Basic)	-1.32	-1.30	-3.60	-58.56	-5.75
EPS (Diluted)	-1.32	-1.30	-3.60	-58.56	-5.75
Free Cash Flow	-40.03	-35.5	-19.1	-16.11	-10.38
Free Cash Flow Per Share	-1.04	-0.94	-0.60	-49.61	-4.41
EBITDA	-50.2	-50.38	-39.12	-18.78	-12.06
D&A For EBITDA	0.49	0.21	0.18	0.03	0
EBIT	-50.69	-50.59	-39.3	-18.82	-12.06

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.